Notably, a matrix metalloproteinase-2-sensitive nanovesicle is developed to enhance photodynamic cancer immunotherapy by targeting cholesterol metabolism in CD8+ T cells and tumor cells within the TME. This evidence concerns the gene CD8A and neoplasm.